Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Stake Boosted by Algert Global LLC

Algert Global LLC boosted its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 401.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,825 shares of the biopharmaceutical company’s stock after purchasing an additional 7,865 shares during the quarter. Algert Global LLC’s holdings in Alnylam Pharmaceuticals were worth $2,702,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the business. Souders Financial Advisors grew its position in shares of Alnylam Pharmaceuticals by 1.0% during the 2nd quarter. Souders Financial Advisors now owns 3,512 shares of the biopharmaceutical company’s stock valued at $853,000 after buying an additional 36 shares during the last quarter. Huntington National Bank grew its holdings in shares of Alnylam Pharmaceuticals by 91.8% during the third quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 45 shares during the last quarter. Lindbrook Capital LLC raised its position in shares of Alnylam Pharmaceuticals by 11.1% during the 3rd quarter. Lindbrook Capital LLC now owns 570 shares of the biopharmaceutical company’s stock worth $157,000 after purchasing an additional 57 shares during the period. V Square Quantitative Management LLC raised its position in shares of Alnylam Pharmaceuticals by 21.9% during the 2nd quarter. V Square Quantitative Management LLC now owns 334 shares of the biopharmaceutical company’s stock worth $81,000 after purchasing an additional 60 shares during the period. Finally, Allspring Global Investments Holdings LLC lifted its holdings in shares of Alnylam Pharmaceuticals by 54.2% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 259 shares of the biopharmaceutical company’s stock worth $63,000 after purchasing an additional 91 shares during the last quarter. Institutional investors own 92.97% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on ALNY. Wolfe Research downgraded Alnylam Pharmaceuticals from a “peer perform” rating to an “underperform” rating in a research note on Tuesday, November 12th. William Blair reaffirmed an “outperform” rating on shares of Alnylam Pharmaceuticals in a report on Tuesday, November 19th. TD Cowen boosted their target price on shares of Alnylam Pharmaceuticals from $282.00 to $371.00 and gave the company a “buy” rating in a research note on Monday, October 21st. HC Wainwright restated a “buy” rating and issued a $400.00 price target on shares of Alnylam Pharmaceuticals in a research note on Monday, November 18th. Finally, Raymond James boosted their price objective on Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the stock an “outperform” rating in a research report on Friday, November 1st. One research analyst has rated the stock with a sell rating, five have given a hold rating and nineteen have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $298.09.

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ:ALNY opened at $253.35 on Wednesday. The company has a market capitalization of $32.68 billion, a PE ratio of -96.70 and a beta of 0.39. The company has a debt-to-equity ratio of 31.64, a quick ratio of 2.69 and a current ratio of 2.75. The stock has a fifty day moving average of $272.74 and a 200-day moving average of $239.37. Alnylam Pharmaceuticals, Inc. has a one year low of $141.98 and a one year high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.36). The company had revenue of $500.90 million during the quarter, compared to analyst estimates of $532.91 million. The firm’s revenue for the quarter was down 33.3% compared to the same quarter last year. During the same period last year, the business earned $1.15 EPS. As a group, equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -2.21 EPS for the current fiscal year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.